Every dialysis patient knows the ritual: a fistful of chalky pills with each meal, swallowing them for one purpose only, grabbing phosphate before food can. What would it take to retire that ritual?
Its sole asset, AP306, is a first-in-class phosphate-transporter inhibitor licensed for global development outside Greater China from Alebund Pharmaceuticals of Shanghai.
A worldwide Phase 2b trial in dialysis patients commenced July 21.
R1 is a Redwood City company built around one molecule with an unusual passport. Discovered by Japan's Chugai Pharmaceutical, developed further by a Chinese kidney-disease specialist, and now licensed onward to an American startup, AP306 carries six decades of pharmaceutical orthodoxy in its crosshairs. The route it traveled explains both the price and the bet.
Sixty years of chalk
When kidneys fail, phosphate stops leaving the body. Chronically elevated serum phosphate is associated with bone disease and vascular calcification, which is why nephrologists have fought it for generations. Their main weapon remains the phosphate binder, compounds R1's own launch release describes bluntly: sixty years as the standard of care, limited by low binding capacity, high pill burden and poor gastrointestinal tolerability.
Binders work chemically. They mix with phosphate in the gut and escort it out unabsorbed, which means the dose must scale with every meal. Coverage of the licensing terms cites estimates that more than 80 percent of hemodialysis patients remain hyperphosphatemic despite this arsenal, in a therapeutic segment worth roughly $1.5 to 2 billion a year. Adherence is the quiet failure point: regimens can reach eight to twelve tablets a day.
A different idea has circulated for years. Rather than mopping up phosphate after it arrives, block the transporters that carry it across the intestinal wall in the first place. Several candidates tried this against a single transporter, NaPi-IIb, and failed to move serum phosphate meaningfully. Chugai's insight, published alongside its chemistry, was that blocking one gate leaves others open. PiT-2, its data suggested, dominates phosphate transporter expression in the human intestine. So the company inhibited three gates at once.
The Chugai molecule that took the scenic route
The compound now called AP306 began life as EOS789 inside Chugai's labs. Its publication trail reads like a careful, unhurried case study in how molecules sometimes change hands twice before finding their market.
- April 2020: Chugai researchers report in Kidney International that EOS789 inhibits all three sodium-dependent phosphate transporters, NaPi-IIb, PiT-1 and PiT-2. In rat models of chronic kidney disease it cuts serum phosphate below normal-control levels, suppresses FGF23 and parathyroid hormone, and limits calcification of the thoracic aorta.
- 2021: A phase 1b crossover trial in hemodialysis patients, led by K.M. Hill Gallant, finds the drug safe with an indication of efficacy, publishing again in Kidney International.
- Date unspecified in public records: Chugai licenses the compound to Alebund Pharmaceuticals, founded in Shanghai in 2018 and focused squarely on kidney disease.
- April 2025: Results of a randomized phase 2a trial conducted at 11 Chinese centers appear in Kidney International Reports.
- March 17, 2026: R1 Therapeutics launches in Redwood City with $77.5 million and exclusive rights outside Greater China.
- June 30, 2026: R1 announces a scientific advisory board staffed with nephrology leadership.
- July 21, 2026: The company announces commencement of its global Phase 2b trial in dialysis patients.
Two handoffs in under a decade is unusual. Each seller kept a reason to care: Alebund retained Greater China rights plus financial participation in the West, while R1 got a molecule with human data already on file. For a Series A-stage company, skipping discovery and early proof-of-mechanism is the entire value proposition.
What the head-to-head actually showed
The phase 2a trial randomized 55 hemodialysis patients with serum phosphate between 5.5 and 9.0 mg/dl, 27 to AP306 and 28 to sevelamer carbonate, a widely used binder, for 12 weeks. It was open-label and active-controlled, run across 11 centers in China. The results favor the transporter approach on every headline measure:
| Endpoint, 12 weeks | AP306, n=27 | Sevelamer, n=28 |
|---|---|---|
| Mean change in serum phosphate | -2.51 mg/dl | -1.08 mg/dl |
| Patients reporting serious adverse events | 0 | 2, 7.1% |
| Diarrhea | 44.4%, mild to moderate | 0% |
| Daily tablet count once stabilized | Below 300 mg, about 3 tablets | Multiple pills with each meal |
A 2.51 mg/dl average reduction against an active comparator is a strong result for this indication, and the gap versus sevelamer widened from treatment week five, when roughly 20% more AP306 patients held the guideline-recommended range. The trade is gastrointestinal: over half the AP306 arm reported digestive side effects, led by diarrhea in 44.4%. Most cases were mild to moderate and resolved without sequelae, according to the investigators. Whether that profile survives contact with a broader population is precisely what a larger, longer trial must answer.
Why the dialysis incumbents wrote the check
Look at the syndicate rather than the size. DaVita Venture Group is the investment arm of one of America's two dominant dialysis providers; U.S. Renal Care runs dialysis clinics nationwide. These are not passive checks. The companies that own the chairs and the patients have an obvious interest in a therapy that could shrink a daily pill stack into three tablets, and their involvement shortens the distance between approval and formulary.
The deal architecture matters too. Coverage of the license terms reports up to $100 million in milestones, tiered royalties in the low double digits on net sales, and an equity stake for Alebund with anti-dilution protection. That structure has become the template of the moment: Reuters counted 38 Chinese biotech out-licensing deals announced in the first months of 2026, on pace to break last year's record of 186. Western buyers get de-risked assets with human data; Chinese sellers keep economics without funding Western trials themselves. Nephrology, long a financing backwater compared with oncology, is getting its turn. As we wrote in August, when LifeMine raised $263 million for transplant-kidney immunosuppressants, capital is rotating into renal medicine from several directions at once.
The bear case reads like a checklist
✅ Arguments for
Superiority over sevelamer, not just placebo, is rare currency in this indication.
Strategic investors on the cap table own the distribution channel AP306 will need.
Confirmation criteria: Phase 2b reproduces the phosphate reduction at scale with a GI profile that does not wreck adherence.
❌ Arguments against
Diarrhea in nearly half of patients is a real-world adherence risk that trial sites manage better than homes do.
The Kidney International Reports discussion states the field's uncomfortable truth plainly: prospective outcome studies showing that lowering phosphate improves cardiovascular events or mortality do not exist yet.
Tenapanor, the last non-binder entrant, shows how slowly nephrologists change prescribing habits.
Disconfirmation criteria: Phase 2b misses superiority, or discontinuation rates spike on GI events.
What Phase 2b has to prove
For investors tracking private markets, four signals matter over the next year: enrollment pace in the global trial, the durability of the phosphate delta, GI-related dropout, and whether regulators engage on a monotherapy label. Krishna Polu, R1's co-founder and chief executive, told launch-day audiences that AP306 should redefine the class if it works. That is founder language, but it rests on an honest observation: the incumbent tool has barely changed since the 1960s, while the failure rate hasn't moved either.
The quieter story is the arbitrage. Alebund converted a Chugai cast-off into a deal with milestones, royalties and equity upside, funded partly by the very dialysis providers who will someday dispense the product. If AP306 succeeds, everyone in the chain gets paid. If it fails, Shanghai still collected its milestones and kept China. Structures like this explain why the out-licensing pipeline keeps swelling regardless of any single trial's fate.
Phase 2b enrollment and completion milestones through 2027
Durability of the -2.5 mg/dl-scale phosphate reduction in a larger cohort
GI discontinuation rate versus the 44.4% diarrhea signal seen in phase 2a
Any prospective outcomes data linking phosphate control to cardiovascular benefit
